immunodefici
viru
hiv
present
studi
screen
plasma
infect
art
individu
neutral
potenti
use
standard
panel
pseudovirus
belong
differ
subtyp
differ
level
neutral
identifi
sampl
good
breadth
neutral
neutral
virus
four
sampl
neutral
even
difficulttoneutr
pseudovirus
great
potenc
gmt
analysi
neutral
specif
indic
four
sampl
antibodi
multipl
epitop
bind
specif
viz
site
glycan
region
membran
proxim
extern
region
mper
find
indic
strong
possibl
identifi
highli
potent
bnab
known
novel
specif
subtyp
c
infect
individu
india
exploit
therapeut
tool
lead
molecul
identif
potenti
epitop
design
protect
vaccin
neutral
plasma
sampl
thirteen
sampl
exclud
test
either
due
insuffici
sampl
volum
due
recent
infect
remain
plasma
sampl
screen
neutral
activ
panel
pseudovirus
list
supplementari
tabl
tabl
fifti
eight
sampl
found
neutral
virus
eight
neutral
pseudovirus
neutral
consid
good
breadth
neutral
defin
montefiori
sampl
test
panel
six
pseudovirus
thirti
plasma
sampl
found
neutral
pseudovirus
six
neutral
pseudovirus
sampl
screen
panel
six
pseudovirus
twelv
sampl
name
neutral
pseudovirus
henc
consid
broadli
crossclad
neutral
bcn
sampl
result
neutral
assay
provid
tabl
heat
map
neutral
activ
panel
pseudovirus
provid
supplementari
fig
potenc
neutral
bcn
sampl
neutral
titrat
assay
perform
bcn
sampl
panel
tier
pseudovirus
list
tabl
two
sampl
titrat
one
two
pseudovirus
due
insuffici
sampl
volum
id
calcul
doserespons
curv
fit
nonlinear
function
use
graphpad
fig
geometr
mean
titer
gmt
calcul
plasma
pseudovirus
tabl
four
plasma
sampl
neutral
pseudovirus
gmt
id
valu
gmt
remain
sampl
rang
thu
bcn
sampl
test
exhibit
high
potenc
neutral
antibodi
linear
peptid
bcn
sampl
test
elisa
linear
peptid
span
full
length
envelop
protein
indian
subtyp
c
clone
order
identifi
bind
specif
antibodi
plasma
eleven
bcn
sampl
use
analysi
one
sampl
could
test
due
insuffici
volum
sampl
antibodi
bound
loop
immunodomin
id
region
three
sampl
antibodi
bound
mper
peptid
fig
bcn
sampl
exhibit
bind
activ
discontinu
epitop
spread
across
hiv
env
none
sampl
antibodi
cytoplasm
tail
ct
envelop
bind
site
antibodi
bcn
plasma
sampl
screen
presenc
antibodi
use
recombin
protein
mutant
form
four
sampl
vari
amount
direct
antibodi
respect
indic
abil
bind
select
wild
type
protein
mutant
form
ie
differ
bind
activ
signific
p
specif
igg
elut
four
sampl
bind
activ
compar
tabl
clinic
demograph
profil
infect
individu
studi
total
sampl
collect
studi
could
test
count
time
sampl
collect
henc
includ
tabl
well
character
mab
fig
b
tabl
neutral
titer
assay
perform
igg
elut
four
bcn
plasma
sampl
sensit
pseudoviru
sensit
resist
pseudoviru
jrfl
wild
type
jrfl
mutant
well
pseudoviru
known
monoclon
antibodi
use
posit
control
known
antibodi
show
stronger
tabl
antibodi
target
glycan
posit
trimer
neutral
assay
perform
bcn
sampl
suffici
volum
plasma
avail
wild
type
subtyp
c
viru
mutant
form
sampl
show
strong
neutral
activ
fig
tabl
four
sampl
show
significantli
lower
level
neutral
neutral
activ
one
sampl
fold
lower
mutant
compar
fold
three
sampl
remain
four
sampl
show
higher
level
neutral
wt
viru
indic
antibodi
sampl
specif
target
glycan
target
region
env
four
sampl
show
vari
level
depend
glycan
studi
understand
whether
glycan
depend
antibodi
individu
similar
belong
seri
perform
neutral
assay
known
literatur
bnab
neutral
subtyp
b
jrfl
wt
strain
due
presenc
glutam
acid
e
posit
howev
e
replac
lysin
k
wt
jrfl
strain
singl
mutat
turn
sensit
neutral
antibodi
therefor
use
two
pseudovirus
jrfl
wt
jrfl
analysi
like
bnab
four
sampl
strongli
neutral
fold
mutant
pseudoviru
jrfl
wt
fig
tabl
neutral
also
perform
identif
posit
depend
use
two
doubl
mutant
jrfl
jrfl
fig
three
four
sampl
show
reduc
neutral
doubl
mutant
fold
reduct
compar
singl
mutant
tabl
one
sampl
show
fold
reduct
neutral
doubl
mutant
also
observ
lower
level
neutral
mutant
viru
seven
eight
bcn
sampl
compar
decreas
fold
three
sampl
fold
four
sampl
show
maximum
reduct
neutral
fold
compar
wt
tabl
mper
specif
neutral
antibodi
identifi
mperspecif
neutral
antibodi
select
three
plasma
sampl
show
bind
overlap
mper
peptid
initi
pepscan
analysi
fig
none
three
sampl
neutral
strain
tabl
show
fold
higher
titer
neutral
chimer
viru
contain
subtyp
b
mper
compar
one
contain
subtyp
c
mper
suggest
presenc
neutral
antibodi
contrast
signific
drop
id
valu
viru
contain
subtyp
c
mper
compar
one
contain
subtyp
b
mper
howev
two
plasma
sampl
neutral
strain
recogn
epitop
wfdit
present
subtyp
b
c
neutral
chimera
virus
report
neutral
mper
chimera
virus
need
necessarili
result
neutral
primari
isol
sinc
chimera
virus
sensit
mab
primari
isol
therefor
evalu
neutral
abil
plasma
elut
polyclon
igg
sampl
use
pindi
full
length
mper
peptid
coat
tosylactiv
dynabead
igg
elut
blank
bead
hhp
sampl
show
neutral
activ
test
pseudovirus
support
tabl
fig
polyclon
igg
elut
exhibit
moder
neutral
breadth
potenc
test
crossclad
pseudoviru
panel
tabl
neutral
virus
except
rhpa
pseudoviru
subtyp
b
indic
presenc
mper
specif
bnab
two
sampl
recent
year
enorm
amount
research
focus
identif
broadli
neutral
antibodi
mani
part
world
sever
broad
potent
neutral
antibodi
identifi
hivinfect
individu
howev
indian
research
line
limit
group
given
preponder
global
epidem
subtyp
c
viru
also
predomin
circul
subtyp
indian
popul
studi
subtyp
c
infect
individu
would
possibl
lead
identif
potent
bnab
novel
epitop
exploit
hiv
vaccin
research
present
studi
plasma
asymptomat
art
subtyp
c
infect
individu
south
indian
cohort
screen
presenc
bnab
twelv
sampl
strongli
neutral
tier
virus
test
categor
studi
broadli
crossclad
neutral
bcn
sampl
previou
studi
also
report
infect
individu
develop
bnab
sometim
cours
infect
interestingli
observ
bcn
sampl
identifi
studi
neutral
subtyp
c
pseudovirus
strongli
endors
recent
report
strain
specif
neutral
potenti
nab
bcn
sampl
identifi
present
studi
character
potenc
determin
id
titer
seven
difficulttoneutr
pseudovirus
four
sampl
demonstr
high
potenc
neutral
gmt
one
sampl
gmt
remain
six
sampl
exhibit
moder
potenc
gmt
rang
find
agreement
previou
report
approxim
infect
individu
may
develop
antibodi
strong
potenc
great
breadth
neutral
pepscan
analysi
show
sampl
antibodi
bound
strongli
id
region
similar
observ
also
made
group
investig
report
infect
individu
harbour
antibodi
gener
nonneutr
region
known
contain
three
epitop
pdrpeg
ieee
erdrd
antibodi
epitop
thought
bind
particl
attach
cell
receptor
gener
antibodi
respons
kennedi
epitop
infect
individu
thought
weak
interestingli
indian
refer
strain
pindi
amino
acid
substitut
result
alter
amino
acid
composit
epitop
pdrlgr
eqdkdr
respect
exhibit
high
bind
affin
pdrlgr
suggest
chang
subtyp
c
relev
improv
bind
antibodi
respons
might
might
translat
inactiv
neutral
mper
compris
last
residu
ectodomain
sever
well
character
nab
like
bind
linear
epitop
mper
studi
three
sampl
show
bind
reactiv
mper
peptid
receptor
target
cell
play
major
role
viral
entri
interact
bind
site
present
hiv
envelop
bnab
identifi
howev
sinc
sever
bnab
greater
breadth
potenc
neutral
isol
infect
individu
etc
two
current
test
use
therapeut
vaccin
first
test
plasma
bind
activ
wild
type
protein
select
bind
specif
bnab
mutant
form
protein
show
decreas
bind
bnab
identifi
four
sampl
contain
antibodi
demonstr
abil
preferenti
bind
wt
protein
mutant
form
order
determin
neutral
potenti
specif
antibodi
sampl
elut
igg
plasma
test
neutral
assay
pseudovirus
two
four
sampl
exhibit
strong
neutral
viru
jrfl
wt
subtyp
b
pseudoviru
diminish
neutral
jrfl
like
observ
provid
clear
evid
show
sampl
contain
specif
antibodi
neutral
abil
find
mirror
landai
et
al
other
although
bind
activ
may
found
infect
individu
reactiv
antibodi
mediat
broad
neutral
detect
individu
major
limit
bind
approach
observ
previou
investig
walker
et
al
bnab
may
bind
protein
necessit
use
addit
recombin
core
molecul
howev
could
perform
experi
adsorb
antibodi
due
insuffici
sampl
volum
well
known
hiv
use
glycan
shield
escap
attack
host
immun
system
glycan
shield
hinder
access
neutral
antibodi
bind
site
thu
identif
bnab
target
critic
glycan
hiv
envelop
could
pave
way
design
effect
vaccin
hiv
potenti
nlink
glycan
posit
hiv
envelop
known
crucial
bind
glycan
depend
antibodi
belong
pgt
seri
respect
evalu
bcn
sampl
identifi
studi
presenc
potenti
nlink
glycan
depend
antibodi
purpos
perform
neutral
assay
subtyp
c
pseudoviru
mutant
form
studi
shown
virus
mutat
posit
loop
escap
neutral
antibodi
identifi
four
sampl
strongli
neutral
show
reduc
level
neutral
mutant
viru
suggest
sampl
like
contain
like
antibodi
one
four
sampl
show
reduct
neutral
compar
indic
strong
specif
antibodi
present
sampl
epitop
addit
four
sampl
also
demonstr
strong
neutral
jrfl
mutant
pseudoviru
compar
wt
jrfl
pseudoviru
provid
support
specif
antibodi
sampl
due
presenc
glutam
acid
e
posit
jrfl
mask
exposur
asparagin
n
glycan
posit
therebi
abrog
bind
like
antibodi
epitop
found
reduct
neutral
activ
plasma
doubl
mutant
jrfl
jrfl
compar
singl
mutant
provid
proof
document
presenc
like
bnab
sampl
interestingli
two
sampl
show
neutral
activ
also
contain
antibodi
seen
previou
experi
four
sampl
show
higher
level
neutral
mutant
viru
wt
viru
indic
possibl
sampl
contain
nab
independ
glycan
target
region
env
pgt
seri
antibodi
pgt
bind
glycan
site
variou
angl
neutral
identifi
antibodi
similar
specif
present
bcn
sampl
analyz
plasma
neutral
activ
subtyp
c
viru
mutant
pseudoviru
seven
bcn
sampl
neutral
indic
presenc
antibodi
belong
pgt
seri
similar
observ
high
frequenc
glycandepend
antibodi
among
subtyp
c
infect
individu
subsaharan
africa
recent
report
landai
et
al
seven
sampl
one
sampl
show
fold
reduct
neutral
mutant
compar
wt
two
sampl
also
show
reduct
fold
neutral
mutant
compar
wt
viru
suggest
possibl
three
sampl
could
contain
antibodi
similar
pgt
seri
antibodi
knowledg
first
studi
india
demonstr
presenc
pgt
seri
bnab
among
infect
individu
countri
tabl
neutral
activ
mperspecif
igg
pseudoviru
panel
neutral
titer
ic
assay
perform
igg
antibodi
concentr
gml
elut
use
mperpeptid
coat
tosyl
activ
myon
dynabead
four
pseudovirus
mulv
ic
valu
gml
shown
bold
format
valu
gml
shown
normal
format
scientif
report
doi
special
interest
notic
sampl
antibodi
multipl
specif
glycan
glycan
three
sampl
show
reactiv
mperspecif
peptid
pepscan
analysi
analyz
neutral
potenti
use
mper
chimera
pseudovirus
found
strongli
neutral
subtyp
b
c
chimer
virus
neutral
weakli
evalu
neutral
abil
igg
elut
two
sampl
neutral
abil
found
show
moder
neutral
breadth
potenc
major
crossclad
pseudovirus
confirm
presenc
mper
specif
bnab
sampl
result
agreement
previou
report
nab
direct
moder
breadth
potenc
neutral
pseudovirus
sinc
mper
peptid
known
play
major
role
fusion
viral
host
cell
membran
find
encourag
character
antibodi
two
sampl
summari
studi
identifi
broad
potent
neutral
antibodi
plasma
subset
infect
individu
india
four
bcn
sampl
neutral
activ
bind
specif
one
vulner
site
env
tabl
one
sampl
found
neutral
activ
bind
specif
four
vulner
site
env
suggest
sampl
worthi
investig
character
investig
also
report
identif
bnab
target
multipl
vulner
site
hiv
envelop
singl
donor
knowledg
first
studi
india
identifi
second
gener
broad
cross
clade
neutral
antibodi
belong
pgt
seri
mper
infect
individu
work
ongo
isol
character
monoclon
antibodi
sampl
centr
kilpauk
medic
colleg
hospit
chennai
india
period
april
septemb
recruit
studi
studi
subject
asymptomat
art
time
sampl
collect
fifteen
millilit
venou
blood
collect
k
edta
treat
blood
collect
tube
plasma
separ
centrifug
g
store
ml
aliquot
use
plasma
sampl
heat
inactiv
hour
use
pseudo
virus
belong
clade
b
c
ae
ag
wt
recombin
protein
obtain
nih
aid
reagent
program
pseudovirus
prepar
cotranfect
penv
env
back
bone
plasmid
cell
use
standard
calcium
phosphat
method
titrat
tzmbl
cell
neutral
potenti
plasma
sampl
determin
base
observ
reduct
luciferas
gene
express
singl
round
infect
tzmbl
cell
envpseudotyp
virus
describ
murin
leukemia
viru
mulv
use
control
viru
peptid
bind
antibodi
elisa
fifteen
amino
acid
long
linear
peptid
amino
acid
overlap
span
entir
length
indian
subtyp
c
viru
synthes
commerci
infin
biotech
resourc
inc
pa
peptid
adsorb
onto
elisa
immuno
maxisorp
plate
thermo
fisher
concentr
gml
mm
nahco
ph
overnight
incub
elisa
perform
describ
previous
map
epitop
specif
sampl
demonstr
good
breadth
potenc
neutral
experi
repeat
three
time
healthi
human
plasma
pool
hhp
includ
neg
control
experi
sampl
subsequ
test
elisa
recombin
protein
look
presenc
bind
site
antibodi
proteinparamagnet
bead
coupl
adsorpt
elut
antibodi
sampl
exhibit
strong
neutral
activ
dilut
dmem
contain
fb
ml
dilut
plasma
incub
ml
bead
room
temperatur
minut
step
repeat
three
time
better
remov
antibodi
bead
coupl
mperspecif
antibodi
store
pb
contain
bsa
sodium
azid
remain
plasma
centrifug
three
time
g
minut
time
remov
residu
dynabead
use
subsequ
elisa
neutral
assay
bsacoat
bead
blank
bead
use
neg
control
proteincoupl
bead
wash
three
time
pb
contain
mm
nacl
pb
antibodi
elut
stepwis
decreas
ph
first
bead
mix
mm
glycinehcl
elut
buffer
ph
second
bead
centrifug
second
held
place
bottom
tube
magnet
acidelut
solut
contain
igg
quickli
remov
place
separ
tube
contain
ml
tri
ph
buffer
reach
ph
process
repeat
three
time
elut
igg
dilut
dmem
concentr
centricon
plu
filter
millipor
corp
subsequ
procedur
perform
bead
elut
ph
recov
igg
resist
elut
ph
igg
fraction
recov
acid
elut
step
combin
concentr
combin
igg
fraction
measur
use
nanodrop
technolog
thermofish
igg
character
elisa
use
protein
doubl
mutant
known
monoclon
neutral
antibodi
mab
bind
specif
use
posit
control
viru
neutral
assay
neutral
potenti
plasma
sampl
evalu
use
standard
neutral
assay
briefli
tzmbl
cell
infect
pesudovirus
presenc
absenc
plasma
hour
l
britelit
perkinelm
substrat
ad
well
l
supernat
transfer
solid
opaqu
plate
luminesc
measur
rel
luciferas
unit
rlu
use
vector
luminomet
perkin
elmer
initi
neutral
screen
assay
perform
plasma
dilut
dilut
subsequ
determin
ic
id
valu
serial
dilut
plasma
sampl
rang
use
antiglycan
antimp
specif
neutral
activ
evalu
use
jrflwt
jrfl
jrfl
jrfl
mper
chimer
construct
polyclon
igg
elut
plasma
sampl
use
tosyl
activ
myon
dynabead
coupl
protein
test
neutral
assay
jrfl
wt
jrfl
pseudovirus
evalu
specif
polyclon
igg
elut
plasma
sampl
use
tosyl
activ
myon
dynabead
coupl
mper
peptid
neutral
abil
ab
determin
pseudoviru
panel
jrfl
rhpa
pindi
evalu
mper
specif
statist
analysi
statist
analysi
perform
use
softwar
graphpad
prism
determin
id
valu
doserespons
curv
fit
nonlinear
regress
signific
calcul
use
ttest
p
consid
statist
signific
